Alphatec Holdings, Inc. (NASDAQ:ATEC) Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC trimmed its holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 95.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 49,743 shares of the medical technology company’s stock after selling 1,044,152 shares during the period. Janus Henderson Group PLC’s holdings in Alphatec were worth $277,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Magnetar Financial LLC acquired a new stake in shares of Alphatec in the second quarter worth approximately $10,957,000. First Eagle Investment Management LLC purchased a new stake in shares of Alphatec during the 2nd quarter valued at $1,071,000. Lighthouse Investment Partners LLC increased its holdings in shares of Alphatec by 257.5% during the 2nd quarter. Lighthouse Investment Partners LLC now owns 208,594 shares of the medical technology company’s stock worth $2,180,000 after buying an additional 150,244 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in shares of Alphatec by 11.3% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company’s stock worth $16,280,000 after buying an additional 297,850 shares during the period. Finally, AlphaCentric Advisors LLC purchased a new position in shares of Alphatec in the 3rd quarter worth $2,057,000. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Alphatec Stock Performance

Shares of ATEC opened at $9.62 on Monday. The firm has a market cap of $1.36 billion, a price-to-earnings ratio of -7.52 and a beta of 1.38. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. The business’s 50 day moving average is $7.98 and its two-hundred day moving average is $8.12. Alphatec Holdings, Inc. has a 52-week low of $4.88 and a 52-week high of $17.34.

Analyst Ratings Changes

ATEC has been the topic of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Alphatec in a research note on Thursday, October 31st. Needham & Company LLC reissued a “buy” rating and issued a $13.00 target price on shares of Alphatec in a research note on Thursday, October 31st. Lake Street Capital decreased their price target on shares of Alphatec from $32.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd. Canaccord Genuity Group reissued a “buy” rating and issued a $20.00 price objective on shares of Alphatec in a research report on Friday, August 30th. Finally, Barclays upped their target price on Alphatec from $19.00 to $20.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 19th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $17.11.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.